| Name | Title | Contact Details |
|---|
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.
Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease.